Which federal agency does Consumer Healthcare Products Association comment on most?

Consumer Healthcare Products Association is most active at the Food and Drug Administration.

← OpenPolis Sign in

Consumer Healthcare Products Association

Unclaimed

Industry

Health, Wellness & Fitness

Staff

1625 Eye St NW, Washington, DC

Phone

+1 202-429-9260

Website

chpa.org

Engagement overview

Consumer Healthcare Products Association has filed 224 public comments across 192 dockets at 9 federal agencies, most actively at the Food and Drug Administration.

Consumer Healthcare Products Association

Engagement overview

Is this your organization?

Agency footprint

Dockets (192)

Requests that FDA, under FDCA §505G(b) (OTC monograph administrative order process), amend OTC Monograph M013 to update Drug Facts labeling for all over-the-counter acetaminophen-containing products. In the alternative, Petitioner asks FDA to initiate such an order on its own

Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments.

Drinking Water Contaminant Candidate List 6 (CCL 6)

Increasing Availability of Nonprescription Drugs; Request for Information

General Considerations for the Use of New Approach Methodologies; Draft Guidance for Industry; Availability

Exploring the Scope of Dietary Supplement Ingredients

Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry; Availability

Medical Devices; Exemptions from Premarket Notification: Class II Devices; Request for Comments

Review of Science on Fluoride in Drinking Water

Menstrual Products - Labeling and Performance Testing Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Food Safety and Inspection Service Ultra-Processed Foods; Request for Information

Onshoring Manufacturing of Drugs and Biological Products; Public Meeting; Request for Comments

Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Personal Protective Equipment, Medical Consumables, Medical Equipment, and Their Parts and Components

Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs

Recommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs; Draft Guidance for Industry; Availability

Tool for the Prioritization of Food Chemicals for Post-Market Assessment

Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments

Over-the-Counter Monograph Condition B001: Single-Unit or Unit-Dose Containers for Over-the-Counter Monograph Drugs in Orally Disintegrating Tablet and Film Dosage Forms

Replacing Color Additives in Approved and Marketed Drug Products; Draft Guidance for Industry; Availability

Transfer of a Premarket Notification (510(k)) Clearance – Questions and Answers

Amending Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use

Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients

Development of an Enhanced Systematic Process for FDA’s Post-Market Assessment of Chemicals in Food; Public Meeting; Request for Comments

Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request

Vinyl Chloride; TSCA Review

Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products

Enhancing Coverage of Preventive Services under the Affordable Care Act

Control of Nitrosamine Impurities in Human Drugs; Guidance for Industry; Availability

Predetermined Change Control Plans for Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability

2024 Special 301 Out-of-Cycle Review of Notorious Markets: Comment Request

Best Practices for Meeting Management; Public Workshop; Request for Comments

Listening Session: Optimizing FDA’s Use of and Processes for Advisory Committees; Public Meeting; Request for Comments

Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use

Cyber Incident Reporting for Critical Infrastructure Act (CIRCIA) Reporting Requirements

Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products; Draft Guidance for Industry; Availability

New Dietary Ingredient Notification Master Files for Dietary Supplements; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Comment Request

Annual Reportable Labeling Changes for NDAs and ANDAs for Nonprescription Drug Products; Draft Guidance for Industry; Availability

Conducting Remote Regulatory Assessments—Questions and Answers; Draft Guidance for Industry; Availability

Food and Drug Administration’s Draft Report and Plan on Best Practices for Guidance; Availability

Medical Devices; General and Plastic Surgery Devices; Classification of Certain Solid Wound Dressings, Wound Dressings Formulated as a Gel, Creams, or Ointment, and Liquid Wound Washes

Quality Considerations for Topical Ophthalmic Drug Products; Draft Guidance for Industry; Availability

Request for Information; Coverage of Over-the-Counter Preventive Services

Advisory Committee; Digital Health Committee; Establishment

Medical Devices; Laboratory Developed Tests

Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Reauthorization of the Over-the-Counter Monograph Drug User Fee program; Public Meeting; Request for Comments

Stakeholder Engagement Opportunity for the Safer Choice and Design for the Environment (DfE) Programs’ Potential Expansion into New Product Categories

Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products: Nonclinical Information; Draft Guidance for Industry; Availability

Nonprescription Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Filing of Color Additive Petition From Environmental Defense Fund, et al.; Request To Revoke Color Additive Listing for Use of Titanium Dioxide in Food

Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability

Marketing Submission Recommendations for a Modification Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

FDA Seeks Public Comment: Increasing Patient Access to At-Home Use Medical Technologies

Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products; Establishment of a Public Docket; Request for Comments

Over-the-Counter Monograph Order Requests (OMORs): Format and Content; Draft Guidance for Industry; Availability

FTC Seek Comments on Green Guides Review, Matter No. P954501

Antigingivitis & Antiplaque-Related Claims

Investigational New Drug Application Annual Reporting

Investigational New Drug Applications; Exemptions for Clinical Investigations to Evaluate a Drug Use of a Product Lawfully Marketed as a Conventional Food, Dietary Supplement, or Cosmetic

List of Highest Priority Devices for Human Factors Review

Changes to Reporting Requirements for Per- and Polyfluoroalkyl Substances; Community Right-to-Know Toxic Chemical Release Reporting

Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act (Edition 5): Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request

Nonprescription Drug Product With an Additional Condition for Nonprescription Use; Proposed Rule

Quantifying Sodium, Potassium, and Phosphorus in Labeling for Human Over-the-Counter and Prescription Drug Products; Draft Guidance for Industry; Availability

Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products

Providing Over-the-Counter Monograph Submissions in Electronic Format; Draft Guidance for Industry; Availability

Revising the National Drug Code Format and Drug Label Barcode Requirements

Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request

Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Prioritizing the Addition of Maximum Daily Exposure Information and Removing Dosage Form Information From the Inactive Ingredient Database; Establishment of a Public Docket; Request for Comments

Medical Devices; Quality System Regulation Amendments

Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry; Availability

Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs; Draft Guidance for Industry; Availability